Myriad Genetics, Inc. (MYGN) said the company is narrowing the range for fiscal full year revenue guidance to total revenue of $753 to $755 million and updating adjusted earnings per share guidance to $1.63 to $1.65. In February, the company projected its fiscal full-year revenue in a range of $750 to $770 million and adjusted earnings per share of $1.63 to $1.68.
from RTT - Earnings http://ift.tt/1Y6mBY5
via IFTTT
No comments:
Post a Comment